Eight Q3 Trial Read-Outs
We have identified eight key trials expected to read out by the end of September 2018. Click on the item to jump straight to the details
RedHill Biopharma Ltd. is in August 2018 expected to report unblinded top-line results from the Phase III MAP US study of RHB-104, an oral antibiotic combination therapy containing rifabutin, clarithromycin and clofazimine. The product is under development for the potential treatment of Mycobacterium avium subspecies paratuberculosis (MAP) infection, which may be a disease-promoting factor in Crohn's disease. The international study in moderate to severely active Crohn’s disease has a primary endpoint of disease remission, defined as Crohn's Disease Activity Index (CDAI) value of less than 150 at week 26.
Two pre-planned analyses by an independent data and safety monitoring board have recommended its continuation. Analysts at Biomedtracker said blinded...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?